Suboxone Tooth Decay Lawsuit: 2026 Case Guide

Quick Answer Box

• What the case is: Thousands of product liability claims allege Indivior failed to warn that Suboxone sublingual film causes severe tooth decay, erosion, and tooth loss. The cases are consolidated in MDL No. 3092.
• Who qualifies: Anyone prescribed Suboxone sublingual film who later experienced documented dental injuries such as cavities, extractions, fractures, or full tooth loss.
• What it may be worth: Individual settlement estimates range from $50,000 to $300,000 or more, depending on the severity of dental damage and documented treatment costs.

The suboxone tooth decay lawsuit has become one of the most closely watched pharmaceutical mass torts in the federal court system heading into 2026. More than 3,000 individual claims have been consolidated in MDL No. 3092 in the Northern District of Ohio, all built on the same core allegation: Indivior knew its sublingual film formulation posed a serious risk to dental health and failed to provide adequate warnings.

The FDA issued a required safety label change in January 2022 after receiving more than 300 adverse event reports of dental problems tied to buprenorphine dissolved under the tongue. Many of those reports described patients with no prior history of dental disease who developed rapid-onset cavities, tooth fractures, and complete tooth loss.

Before you go further, consider reading Cash App Lawsuit 2026: Settlement, Claims & Payouts

What makes this litigation particularly significant in 2026 is the convergence of bellwether trial preparation, mounting plaintiff counts, and a legal marketing ecosystem that has made Suboxone claims one of the highest-volume mass tort campaigns in the country. This guide covers every active angle of the case, from court specifics and settlement projections to eligibility standards and the marketing machinery driving case acquisition.

For anyone who took Suboxone film and lost teeth, the question is no longer whether this litigation exists. The question is where it stands right now and what a claim might be worth.

Suboxone Tooth Decay Lawsuit

The suboxone tooth decay lawsuit is a consolidated federal litigation alleging that Indivior Inc. failed to warn patients and prescribers about the dental risks of its sublingual film product. Each claim is an individual product liability action, not a single class action, but all share the same factual core.

Plaintiffs contend that the acidic pH of the sublingual film, combined with prolonged mucosal contact, erodes tooth enamel at rates far exceeding what patients or dentists would expect. The drug's prescribing information did not carry a dental warning until the FDA mandated one in January 2022, years after the product reached the market in film form.

The litigation traces back to early individual filings in 2023, with the Judicial Panel on Multidistrict Litigation (JPML) transferring cases to the Northern District of Ohio in February 2024. Judge David A. Ruiz was assigned to oversee the consolidated docket.

*Attorney Insight: Attorneys handling these claims emphasize that the strength of each case depends on documented dental records showing a timeline of dental deterioration that correlates with Suboxone film use.*

Key Facts at a Glance:

Suboxone Tooth Decay Lawsuit Settlement Amounts 2026

No global settlement fund has been established in MDL 3092 as of early 2026. Settlement amounts remain projections based on case severity tiers, comparable pharmaceutical MDL outcomes, and plaintiff attorneys' publicly stated expectations.

Mass tort attorneys have categorized potential payouts into tiers based on the extent of dental damage. The logic follows a familiar pharmaceutical litigation model: the more invasive the dental treatment required, the higher the individual claim value.

Comparable MDLs offer some guidance. The Zantac MDL and 3M earplug litigation both produced settlement structures that rewarded claimants with documented medical evidence and clear causation timelines. Suboxone cases with dental records spanning the full treatment period are expected to command higher values.

*Attorney Insight: Attorneys handling these claims note that cases involving full-mouth reconstruction or multiple tooth extractions consistently receive the highest tier designations in mass tort settlement grids.*

Projected Settlement Tiers:

These figures remain estimates. Actual values will depend on bellwether trial outcomes and Indivior's willingness to negotiate.

Who Qualifies for Suboxone Tooth Decay Lawsuit

Anyone who was prescribed Suboxone sublingual film and then developed significant dental problems may qualify. The key word is film. Suboxone tablets are generally not included in this litigation.

Qualification hinges on three factors: use of the film formulation, documented dental injury, and a plausible timeline linking the two. Claimants do not need to prove they had perfect dental health before taking Suboxone, but records showing a marked decline during or after film use strengthen the claim substantially.

Most plaintiff firms screen for the following criteria during intake:

• Prescribed Suboxone sublingual film (not tablets)
• Experienced dental injuries such as cavities, tooth decay, erosion, fractures, or extractions
• Dental problems developed during or after Suboxone film use
• Can provide dental records from before and during treatment
• Have not already settled a Suboxone dental claim independently

*Attorney Insight: Attorneys handling these claims stress that pre-existing dental conditions do not automatically disqualify a claimant, but they do require careful documentation to separate prior damage from Suboxone-related harm.*

Certain populations are especially well-represented in the plaintiff pool. Patients prescribed Suboxone for opioid use disorder who took the film daily for months or years report the most severe outcomes.

Litigation Watch: The litigation remains in active pre-trial proceedings with no settlement fund yet created, projected individual payouts ranging from $50,000 to $300,000+, and a qualification standard centered on sublingual film use with documented dental harm.

Suboxone Tooth Decay Lawsuit Eligibility

Eligibility for the suboxone tooth decay lawsuit depends on specific medical and legal criteria that plaintiff firms and the MDL court use to assess claim viability. Meeting the basic intake criteria is step one. Surviving case-specific Daubert challenges on causation evidence is the deeper legal question Indivior will push.

From the plaintiff's side, eligibility requires:

The distinction between film and tablet matters because the sublingual film's mechanism of delivery keeps the acidic compound in direct contact with teeth and gums for an extended period. Tablets dissolve differently and are not the primary target of this litigation.

Indivior is expected to challenge eligibility at scale by arguing that opioid users already face elevated dental risks due to lifestyle factors, dry mouth from other medications, and baseline health conditions. Plaintiff attorneys counter with the FDA's own 2022 finding that dental injuries occurred even in patients with no prior dental history.

*Attorney Insight: Attorneys handling these claims note that pharmacy dispensing records and prescription histories are often the most efficient way to prove film use, since patients may not remember which formulation they received.*

Class Action Lawsuit Suboxone Tooth Decay

The suboxone litigation is not a class action in the traditional sense. It is a multidistrict litigation (MDL), which operates under a fundamentally different legal structure.

In a class action, one or a few named plaintiffs represent an entire class of similarly situated people. The outcome, whether a settlement or a verdict, applies uniformly. In an MDL, each plaintiff retains an individual case with individual damages. The MDL consolidates pre-trial discovery and motions for efficiency, but each claim rises or falls on its own facts.

This distinction matters for payout calculations. Class action members typically receive identical per-person amounts from a common fund. MDL plaintiffs can receive vastly different amounts based on injury severity, strength of documentation, and state law.

Class Action vs. MDL Comparison:

The "class action lawsuit suboxone tooth decay" search query reflects a common public misunderstanding. The legal reality is that MDL 3092 preserves each plaintiff's right to individual damages while streamlining the litigation process.

*Attorney Insight: Attorneys handling these claims explain that the MDL structure generally benefits plaintiffs with severe injuries, because their individual claim values are not averaged down by less-injured members of a class.*

Suboxone MDL 3092 Update 2026

MDL No. 3092 is assigned to Judge David A. Ruiz in the U.S. District Court for the Northern District of Ohio, Eastern Division. As of early 2026, the case is in active pre-trial proceedings with bellwether case selection and expert discovery ongoing.

The JPML centralized the litigation in February 2024 after finding that the growing number of Suboxone dental injury cases involved common questions of fact. Since then, the Plaintiffs' Steering Committee (PSC) has been appointed and has been coordinating discovery across all consolidated cases.

Key procedural milestones reached or expected in 2026:

• Fact discovery in bellwether cases substantially complete
• Expert discovery and Daubert motions on causation experts expected mid-2026
• Bellwether trial pool selected from cases representing a range of injury severity
• First bellwether trial anticipated in late 2026 or early 2027, subject to court scheduling orders

The docket reflects active motion practice on both sides. Indivior has challenged plaintiff expert methodologies, while plaintiffs have sought broader document production related to Indivior's internal knowledge of the film's acidic pH and dental risk data.

*Attorney Insight: Attorneys handling these claims view the Daubert phase as the most critical juncture in 2026, because the admissibility of plaintiff dental and pharmacological experts will likely determine whether Indivior faces trial pressure or gains leverage to limit settlement exposure.*

Litigation Watch: The MDL remains a true individual-claim mass tort (not a class action), Judge Ruiz is overseeing active pre-trial work in the Northern District of Ohio, and expert discovery and Daubert challenges will define the 2026 trajectory of the case.

Suboxone Lawsuit Bellwether Trial 2026

Bellwether trials are test cases selected to represent the broader plaintiff pool. Their outcomes do not bind other plaintiffs, but they send powerful signals about how juries view the evidence. For Suboxone, the first bellwether trial is expected to be scheduled for late 2026 or early 2027.

The bellwether selection process in MDL 3092 follows a standard protocol. Both sides propose candidate cases. The court selects a small group, typically 4 to 8 cases, that reflect a spectrum of injury severity, geographic diversity, and factual variation. These cases then proceed through full individual discovery and trial preparation.

Historically, bellwether verdicts have a decisive effect on settlement negotiations. In the Johnson & Johnson talcum powder MDL, early plaintiff verdicts in the tens of millions accelerated global settlement talks. Conversely, defense verdicts in the Zantac litigation contributed to claims being dismissed.

*Attorney Insight: Attorneys handling these claims point out that bellwether cases with strong before-and-after dental imaging and clear prescription records are the most likely to produce plaintiff-favorable verdicts, which in turn drive settlement values upward for the entire docket.*

The stakes of the bellwether phase cannot be overstated. If a jury returns a large plaintiff verdict, the economics shift dramatically in favor of a global settlement.

Suboxone Tooth Decay Lawsuit Payout Per Person

Individual payout amounts in the suboxone tooth decay lawsuit will vary widely based on documented injury severity. No per-person payments have been distributed yet, because the litigation has not reached the settlement phase.

The per-person payout model in pharmaceutical MDLs typically follows a tiered point system. Each plaintiff is assigned points based on:

• Type and number of dental procedures (extractions, root canals, crowns, implants, dentures)
• Out-of-pocket dental costs already incurred
• Duration of Suboxone film use
• Age at time of injury (younger plaintiffs with decades of dental impact ahead may receive more)
• Strength of causation evidence (clear timeline, no competing causes)

Based on comparable mass tort settlements and attorney projections:

These are pre-settlement projections. Actual payouts will depend on bellwether trial results, Indivior's financial capacity, and the total number of qualified claims.

*Attorney Insight: Attorneys handling these claims emphasize that per-person payouts in mass torts are inversely related to total claim volume; the more claimants who qualify, the more pressure there is on any finite settlement fund.*

You may want to read Eli Lilly Lawsuit 2026: Claims, Payouts & Who Qualifies

Suboxone Tooth Decay Lawsuit Deadline

There is no single federal deadline for filing a suboxone tooth decay claim. The filing deadline depends on the statute of limitations in the state where the plaintiff resides or where the injury occurred.

Most states apply a 2 to 3 year statute of limitations for product liability or personal injury claims. The clock typically starts on the discovery date, meaning the date the plaintiff knew or should have known that Suboxone caused their dental injury. The FDA's January 2022 warning is a critical marker, because defendants may argue that all patients were on notice as of that date.

Key Deadline Considerations:

• If the discovery date is tied to the January 2022 FDA warning, some state deadlines may have already passed
• Many states apply a discovery rule that delays the start of the clock until the patient actually connects the injury to the product
• Tolling agreements between plaintiff firms and Indivior may extend deadlines for some claimants

Filing sooner rather than later is strongly advisable. Tolling agreements are not guaranteed, and late filers risk procedural dismissal.

*Attorney Insight: Attorneys handling these claims urge potential plaintiffs not to assume the deadline has passed without consulting a lawyer, because individual discovery dates and state-specific tolling doctrines can extend the window.*

Litigation Watch: Per-person payouts will be tiered by injury severity with catastrophic cases projected above $250,000, filing deadlines vary by state with some already at risk, and the bellwether trial phase is the next major inflection point for the entire docket.

How to File Suboxone Tooth Decay Lawsuit

Filing a suboxone tooth decay lawsuit begins with retaining a plaintiff attorney who is either a member of the Plaintiffs' Steering Committee in MDL 3092 or works with a firm that feeds cases into the MDL. Individual claimants do not file directly into the MDL on their own.

Step-by-step filing process:

1. Contact a mass tort attorney experienced in pharmaceutical product liability
2. Complete a case evaluation (typically a questionnaire covering Suboxone use history, dental injuries, and treatment timeline)
3. Provide dental and prescription records (attorney's team will request these from providers and pharmacies)
4. Sign a retainer agreement (most Suboxone attorneys work on contingency, meaning no upfront fees)
5. Attorney files the complaint in federal court, which is then transferred to MDL 3092
6. Case enters MDL pre-trial track and is subject to the court's scheduling orders

Most plaintiff firms handle the entire records-gathering process. Patients do not need to obtain their own medical files, though having them speeds intake.

*Attorney Insight: Attorneys handling these claims report that the most common reason for delayed filing is the patient's assumption that they need to gather their own records before calling a lawyer, when in fact the attorney's staff handles that process.*

Suboxone Tooth Decay Lawsuit Statute of Limitations

The statute of limitations for a suboxone tooth decay lawsuit is the state-imposed deadline for bringing a legal claim. Missing this deadline typically results in permanent forfeiture of the right to sue, regardless of how strong the underlying case is.

Product liability statutes of limitations range from 1 year (Kentucky, Louisiana, Tennessee) to 6 years (Maine, North Dakota) depending on the state. Most fall in the 2 to 3 year range.

The critical question for Suboxone claimants is when the clock starts. Two competing theories apply:

• Date of injury: The clock starts when the dental damage occurred (often hard to pinpoint)
• Date of discovery: The clock starts when the plaintiff discovered or reasonably should have discovered that Suboxone caused the damage

The FDA's January 12, 2022 safety communication is the most commonly cited discovery trigger. Defendants will likely argue that any patient (or their dentist) who continued using Suboxone after that date was on constructive notice.

State-by-State Snapshot:

*Attorney Insight: Attorneys handling these claims warn that even states with generous limitation periods may apply a "statute of repose" that imposes an absolute outer deadline regardless of when the injury was discovered.*

Patients who suspect they may be approaching a deadline should seek legal counsel immediately. Waiting to see how the MDL develops is a dangerous strategy if the statute of limitations is about to expire.

Suboxone Dental Problems FDA Warning

The FDA issued a required safety label change for buprenorphine medicines dissolved in the mouth on January 12, 2022. This communication identified a "risk of dental problems" including tooth decay, cavities, oral infections, and tooth loss.

The agency reviewed its adverse event reporting system (FAERS) and identified more than 300 cases of dental adverse events in patients using sublingual or buccal buprenorphine products. Of those, 131 cases were classified as serious. The FDA specifically noted that dental problems occurred even in patients with no prior history of dental issues.

This warning is central to the litigation for two reasons:

1. It supports the plaintiff argument that Indivior knew or should have known about the risk before 2022
2. It may set the "discovery date" for statute of limitations purposes

FDA Warning Key Points:

Before this warning, the Suboxone sublingual film label contained no specific dental warning. Plaintiffs argue this omission constitutes a failure to warn under product liability law.

*Attorney Insight: Attorneys handling these claims treat the FDA's 2022 communication as the strongest single piece of evidence in the litigation, because it establishes both the risk and Indivior's prior silence about it.*

Litigation Watch: The statute of limitations varies dramatically by state and may have already expired for some claimants, the FDA's January 2022 warning is both the best evidence for plaintiffs and the likely trigger defendants will use to argue deadlines have passed, and immediate legal consultation is advisable for anyone uncertain about their filing window.

Suboxone Tooth Decay Lawsuit Legal Marketing

The suboxone tooth decay lawsuit has become one of the most heavily marketed mass tort cases in the legal advertising market. Legal marketing spend for Suboxone dental injury leads surged beginning in late 2023 and has remained elevated through 2026.

This phenomenon occurs because the case combines several factors that make it attractive for law firm advertising: a large potential plaintiff pool (millions of Americans have been prescribed Suboxone), a clear and sympathetic injury (tooth loss), strong causation evidence (FDA warning), and a well-funded defendant.

Why Suboxone ranks high in legal marketing spend:

• Large addressable market: Millions of buprenorphine prescriptions dispensed annually
• High emotional impact: Dental disfigurement is visible and relatable to juries
• Strong FDA evidence: January 2022 warning provides clear regulatory backing
• Contingency economics: Projected settlement values justify high acquisition costs

Legal marketing for mass torts operates through television commercials, paid search advertising, social media campaigns, and lead generation networks. For Suboxone, the cost per qualified lead has been reported in industry publications at $150 to $500+, depending on lead quality and exclusivity.

*Attorney Insight: Attorneys handling these claims note that the legal marketing landscape for Suboxone cases has become intensely competitive, with lead acquisition costs rising as more firms enter the plaintiff pool.*

The marketing intensity also serves as a barometer of attorney confidence. Firms would not spend millions acquiring Suboxone leads if they did not expect the litigation to produce substantial settlement returns.

Suboxone Tooth Decay Lawsuit Mass Tort Marketing

Mass tort marketing for suboxone tooth decay claims operates as a distinct industry within the legal services ecosystem. It involves coordination among trial attorneys, marketing agencies, lead generation companies, and case management platforms.

The mass tort marketing cycle for Suboxone follows a well-established pattern:

The Suboxone mass tort has attracted both established mass tort firms and newer entrants. Established firms with PSC positions have a structural advantage, because their involvement in bellwether preparation gives them early access to discovery materials and settlement intelligence.

*Attorney Insight: Attorneys handling these claims observe that the quality of mass tort marketing directly affects case outcomes, because poorly screened leads waste litigation resources and can weaken a firm's overall docket.*

Marketing ethics are also under scrutiny. State bar associations have increased oversight of mass tort advertising, particularly around claims that guarantee specific settlement amounts or create misleading impressions about case timelines.

Suboxone Tooth Decay Lawsuit Mass Tort Case Leads

Mass tort case leads for suboxone tooth decay claims are the commercial engine driving plaintiff recruitment. A "lead" in this context is a prospective claimant who has responded to legal advertising and provided initial information about their Suboxone use and dental injuries.

Lead quality tiers in the Suboxone mass tort:

The cost-per-lead economics reflect the projected settlement value per case. If the average payout is expected to be $100,000 and the attorney's contingency fee is 33% to 40%, a firm can justify spending $500 to $1,000 to acquire a case that generates $33,000 to $40,000 in fees.

Lead generation companies in the mass tort space operate under varying levels of regulatory oversight. Reputable companies comply with the Telephone Consumer Protection Act (TCPA) and state bar advertising rules. Less scrupulous operators may use misleading advertising, robo-calls, or data harvesting techniques.

For a deeper understanding, check Immuno 150 Lawsuit: 2026 Update, Claims & Settlement

*Attorney Insight: Attorneys handling these claims emphasize that lead source matters, because cases acquired through deceptive marketing tactics can face judicial scrutiny and may be challenged during the claims administration process.*

The volume of Suboxone leads entering the market in 2026 is expected to increase as bellwether trial dates approach. Trial proximity typically accelerates both advertising spend and plaintiff recruitment.

Litigation Watch: Suboxone has become one of the most expensive and competitive mass tort marketing campaigns in the legal industry, lead costs range from $50 to $1,000+ depending on qualification level, and lead quality directly affects litigation outcomes and settlement leverage.

Suboxone Tooth Decay Lawsuit Marketing Campaigns

Marketing campaigns for the suboxone tooth decay lawsuit span multiple channels and formats. The structure of these campaigns reveals how mass tort litigation is shaped not just in courtrooms but in advertising markets.

Primary campaign channels:

• Television: 30-second and 60-second spots on daytime and cable networks remain the highest-volume channel for mass tort plaintiff recruitment
• Paid search (Google Ads): Keyword bids for "Suboxone lawsuit" and related terms run $50 to $150 per click in competitive markets
• Social media (Facebook, Instagram, YouTube): Targeted ads using demographic and behavioral data to reach likely Suboxone users
• Direct mail: Letters sent to patients identified through pharmacy data partnerships (subject to HIPAA and state privacy rules)
• Programmatic display: Banner ads on health, recovery, and legal information websites

Campaign effectiveness is measured by cost per retained case, not just cost per lead. A campaign that generates 1,000 leads but only 50 signed retainers has a very different ROI profile than one generating 200 leads with 100 retainers.

*Attorney Insight: Attorneys handling these claims report that the most effective campaigns combine multiple channels, with television driving awareness and digital ads capturing intent-driven searches from viewers who saw a TV spot.*

Regulatory compliance is a growing concern. The FTC and state attorneys general have investigated mass tort advertising that makes specific settlement guarantees. Ethical campaigns present factual information about the litigation without promising outcomes.

Suboxone Lawsuit Tooth Decay

The phrase "suboxone lawsuit tooth decay" captures the central factual claim in this litigation: that the drug Suboxone, delivered as a sublingual film, causes tooth decay. The scientific and legal case for this claim rests on three pillars.

Pillar 1: The pharmacological mechanism. Suboxone sublingual film has a measured pH of approximately 3.4, making it mildly acidic. When placed under the tongue and allowed to dissolve over several minutes, it bathes teeth and gum tissue in an acidic environment. Repeated daily exposure, often for months or years, erodes enamel.

Pillar 2: The epidemiological evidence. The FDA's review of adverse events found dental injuries across a broad patient population, including individuals with no prior dental disease. This undermines the defense argument that dental damage is attributable to lifestyle factors alone.

Pillar 3: The labeling failure. Prior to January 2022, the Suboxone film label did not warn of dental risks. Plaintiffs argue this constitutes a textbook failure to warn under both strict liability and negligence theories.

*Attorney Insight: Attorneys handling these claims view the labeling gap as the single most compelling element of the case, because Indivior's own regulatory filings show the company had data on oral health effects but did not add warnings.*

This three-pillar framework is the foundation of every complaint filed in MDL 3092. Each individual case layers personal dental records and treatment costs on top of these common facts.

Litigation Watch: The scientific case linking Suboxone film to tooth decay rests on the drug's acidic pH, the FDA's adverse event data, and the absence of any dental warning before 2022, and this three-pillar framework anchors every individual complaint in MDL 3092.

Frequently Asked Questions

Is the Suboxone tooth decay lawsuit still accepting new claims in 2026?

Yes, new claims are still being filed into MDL 3092 as of 2026.

However, state-specific statutes of limitations may have expired for some claimants, particularly those in states with 2-year deadlines measured from the January 2022 FDA warning.

Anyone considering a claim should consult a mass tort attorney immediately to determine their filing window.

How much is the average Suboxone tooth decay lawsuit payout per person?

No settlements have been paid yet, so there is no confirmed average.

Attorney projections range from $10,000 for mild cases to $300,000+ for catastrophic dental injuries requiring full-mouth reconstruction.

Actual amounts will depend on bellwether trial results, total claim volume, and individual case strength.

What dental injuries qualify for the Suboxone lawsuit?

Qualifying injuries include tooth decay, cavities, enamel erosion, tooth fractures, tooth loss, extractions, root canals, crowns, and the need for dentures or implants.

The injuries must be linked to use of Suboxone sublingual film specifically, not tablets.

Dental records documenting the onset and progression of damage during Suboxone use are essential.

Is the Suboxone lawsuit a class action or mass tort?

MDL 3092 is a mass tort, not a class action.

Each plaintiff retains an individual claim with individual damages, unlike a class action where all members receive the same outcome.

The MDL structure consolidates pre-trial proceedings for efficiency while preserving each person's right to their own recovery.

What is the statute of limitations for filing a Suboxone tooth decay claim?

The deadline varies by state, ranging from 1 year to 6 years depending on the jurisdiction and applicable legal theory.

Most states apply a 2 to 3 year period starting from the date the plaintiff discovered or should have discovered the connection between Suboxone and dental damage.

The January 2022 FDA warning is likely to be cited as the discovery trigger in many cases.

How long will the Suboxone tooth decay lawsuit take to settle?

No global settlement is expected before the first bellwether trial, which is anticipated in late 2026 or early 2027.

If bellwether results favor plaintiffs, settlement negotiations could begin in earnest in 2027, with payouts potentially following in 2027 to 2028.

Mass tort timelines are inherently unpredictable and depend on trial outcomes, appeals, and the volume of qualified claims.

Closing

The Suboxone tooth decay litigation is entering its most consequential phase. Bellwether trials, expert challenges, and rising claim counts will shape whether 2026 becomes the year this case moves toward resolution or extends further into contested territory.

Anyone who took Suboxone sublingual film and experienced dental damage should assess their filing window now, not after a verdict makes headlines. The statute of limitations is unforgiving, and it runs regardless of whether a settlement is close.

Consulting a mass tort attorney who handles pharmaceutical product liability cases in MDL 3092 is the concrete next step for any potential claimant.

Also worth exploring: Deel Rippling Lawsuit: Full Case Breakdown 2026